Gene augmentation therapy as a strategy to treat alpha-1 antitrypsin (AAT) deficiency has reached phase 2 clinical testing in humans. Sustained serum levels of AAT have been observed beyond one year after intramuscular administration of a recombinant adeno-associated virus (rAAV) vector expressing the AAT gene. In this study, sequential muscle biopsies obtained at 3 and 12 months after vector injection were examined for the presence of rAAV vector genomes. Each biopsy sample contained readily detectable vector DNA, the majority of which existed as double-stranded supercoiled and open circular episomes. Episomes persisted through 12 months, although at slightly lower levels than observed at 3 months. There was a clear dose response when comparing the low- and mid-vector-dose groups to the high-dose group. The highest absolute copy numbers were found in a high-dose subject, and serum AAT levels at 12 months confirmed that the high-dose group also had the highest sustained serum AAT levels. Sequence analysis revealed that the vast majority of episomes contained double-D inverted terminal repeats ranging from fully intact to severely deleted. Molecular clones of vector genomes derived directly from the biopsies were transcriptionally active, potentially identifying them as the source of serum AAT in the trial subjects.
StollerJK, AboussouanLS. A review of alpha1-antitrypsin deficiency. Am J Respir Crit Care Med, 2012; 185:246–259.
3.
StrangeC, BeikoT. Treatment of alpha-1 antitrypsin deficiency. Semin Respir Crit Care Med, 2015; 36:470–477.
4.
TracletJ, DelavalP, TerriouxP, et al.Augmentation therapy of alpha-1 antitrypsin deficiency associated emphysema. Rev Mal Respir, 2015; 32:435–446.
5.
SongS, MorganM, EllisT, et al.Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors. Proc Natl Acad Sci USA, 1998; 95:14384–14388.
6.
SongS, Scott-JorgensenM, WangJ, et al.Intramuscular administration of recombinant adeno-associated virus 2 alpha-1 antitrypsin (rAAV-SERPINA1) vectors in a nonhuman primate model: Safety and immunologic aspects. Mol Ther, 2002; 6:329–335.
7.
PoirierAE, CombeeLA, MArtionAT, et al.Toxicology and biodistribution studies of a recombinant adeno-associated virus 2 (rAAV2) alpha-1 antitrypsin (AAT) vector. Mol Ther, 2004; 9:S40.
8.
BrantlyML, ChulayJD, WangL, et al.Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc Natl Acad Sci USA, 2009; 106:16363–16368.
9.
BrantlyML, SpencerLT, HumphriesM, et al.Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alphal-antitrypsin (AAT) vector in AAT-deficient adults. Hum Gene Ther, 2006; 17:1177–1186.
10.
DeBP, HeguyA, HackettNR, et al.High levels of persistent expression of alpha1-antitrypsin mediated by the nonhuman primate serotype rh.10 adeno-associated virus despite preexisting immunity to common human adeno-associated viruses. Mol Ther, 2006; 13:67–76.
11.
Liqun WangR, McLaughlinT, CossetteT, et al.Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol Ther, 2009; 17:81–87.
12.
HalbertCL, MadtesDK, VaughanAE, et al.Expression of human alpha1-antitrypsin in mice and dogs following AAV6 vector-mediated gene transfer to the lungs. Mol Ther, 2010; 18:1165–1172.
13.
ChulayJD, YeGJ, ThomasDL, et al.Preclinical evaluation of a recombinant adeno-associated virus vector expressing human alpha-1 antitrypsin made using a recombinant herpes simplex virus production method. Hum Gene Ther, 2011; 22:155–165.
14.
FlotteTR, TrapnellBC, HumphriesM, et al.Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing alpha1-antitrypsin: Interim results. Hum Gene Ther, 2011; 22:1239–1247.
SchneppBC, ClarkKR, KlemanskiDL, et al.Genetic fate of recombinant adeno-associated virus vector genomes in muscle. J Virol, 2003; 77:3495–3504.
17.
SchneppBC, JensenRL, ChenCL, et al.Characterization of adeno-associated virus genomes isolated from human tissues. J Virol, 2005; 79:14793–14803.
18.
SchneppBC, JensenRL, ClarkKR, et al.Infectious molecular clones of adeno-associated virus isolated directly from human tissues. J Virol, 2009; 83:1456–1464.
19.
UmekawaT, KohriK, AmasakiN, et al.Sequencing of a urinary stone protein, identical to alpha-one antitrypsin, which lacks 22 amino acids. Biochem Biophys Res Commun, 1993; 193:1049–1053.
20.
BeaudoingE, FreierS, WyattJR, et al.Patterns of variant polyadenylation signal usage in human genes. Genome Res, 2000; 10:1001–1010.
21.
Coura RdosS, NardiNB. The state of the art of adeno-associated virus-based vectors in gene therapy. Virol J, 2007; 4:99.
AalbersCJ, TakPP, VervoordeldonkMJ. Advancements in adeno-associated viral gene therapy approaches: Exploring a new horizon. F1000 Med Rep, 2011; 3:17.
24.
LoringHS, FlotteTR. Current status of gene therapy for alpha-1 antitrypsin deficiency. Expert Opin Biol Ther, 2015; 15:329–336.
25.
SchneppBC, JohnsonPR. Vector-mediated antibody gene transfer for infectious diseases. Adv Exp Med Biol, 2015; 848:149–167.
26.
HastieE, SamulskiRJ. Adeno-associated virus at 50: A golden anniversary of discovery, research, and gene therapy success—a personal perspective. Hum Gene Ther, 2015; 26:257–265.
27.
NowrouziA, Penaud-BudlooM, KaeppelC, et al.Integration frequency and intermolecular recombination of rAAV vectors in non-human primate skeletal muscle and liver. Mol Ther, 2012; 20:1177–1186.
28.
MannoCS, ChewAJ, HutchisonS, et al.AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood, 2003; 101:2963–2972.
29.
JiangH, PierceGF, OzeloMC, et al.Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B. Mol Ther, 2006; 14:452–455.
30.
StroesES, NiermanMC, MeulenbergJJ, et al.Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients. Arterioscler Thromb Vasc Biol, 2008; 28:2303–2304.
31.
MingozziF, MeulenbergJJ, HuiDJ, et al.AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood, 2009; 114:2077–2086.
32.
Penaud-BudlooM, Le GuinerC, NowrouziA, et al.Adeno-associated virus vector genomes persist as episomal chromatin in primate muscle. J Virol, 2008; 82:7875–7885.
33.
DuanD, SharmaP, YangJ, et al.Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. J Virol, 1998; 72:8568–8577.
34.
AfioneSA, ConradCK, KearnsWG, et al.In vivo model of adeno-associated virus vector persistence and rescue. J Virol, 1996; 70:3235–3241.
35.
SongS, LaipisPJ, BernsKI, et al.Effect of DNA-dependent protein kinase on the molecular fate of the rAAV2 genome in skeletal muscle. Proc Natl Acad Sci USA, 2001; 98:4084–4088.
36.
FlotteTR, SchwiebertEM, ZeitlinPL, et al.Correlation between DNA transfer and cystic fibrosis airway epithelial cell correction after recombinant adeno-associated virus serotype 2 gene therapy. Hum Gene Ther, 2005; 16:921–928.
37.
YangJ, ZhouW, ZhangY, et al.Concatamerization of adeno-associated virus circular genomes occurs through intermolecular recombination. J Virol, 1999; 73:9468–9477.
38.
SunX, LuY, BishLT, et al.Molecular analysis of vector genome structures after liver transduction by conventional and self-complementary adeno-associated viral serotype vectors in murine and nonhuman primate models. Hum Gene Ther, 2010; 21:750–761.
39.
McCartyDM, FuH, MonahanPE, et al.Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther, 2003; 10:2112–2118.
40.
ChoiVW, SamulskiRJ, McCartyDM. Effects of adeno-associated virus DNA hairpin structure on recombination. J Virol, 2005; 79:6801–6807.
41.
DuanD, SharmaP, DudusL, et al.Formation of adeno-associated virus circular genomes is differentially regulated by adenovirus E4 ORF6 and E2a gene expression. J Virol, 1999; 73:161–169.
42.
YanZ, ZakR, ZhangY, et al.Inverted terminal repeat sequences are important for intermolecular recombination and circularization of adeno-associated virus genomes. J Virol, 2005; 79:364–379.
43.
ChenuaudP, LarcherT, RabinowitzJE, et al.Optimal design of a single recombinant adeno-associated virus derived from serotypes 1 and 2 to achieve more tightly regulated transgene expression from nonhuman primate muscle. Mol Ther, 2004; 9:410–418.
44.
RiveraVM, GaoGP, GrantRL, et al.Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. Blood, 2005; 105:1424–1430.
45.
ToromanoffA, CherelY, GuilbaudM, et al.Safety and efficacy of regional intravenous (r.i.) versus intramuscular (i.m.) delivery of rAAV1 and rAAV8 to nonhuman primate skeletal muscle. Mol Ther, 2008; 16:1291–1299.
